ABL Bio Inc Ordinary Shares 298380
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- ₩31,300.00
- Day Range
- ₩31,550.00–33,050.00
- 52-Week Range
- —–—
- Bid/Ask
- ₩32,450.00 / ₩32,500.00
- Market Cap
- ₩1.56 Tril
- Volume/Avg
- 1.3 Mil / 2.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- 374.65
- Price/Sales
- 47.26
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline products include ABL001 an Bispecific Antibody, ABL201-205 an Antibody Drug Conjugate, T cell engager, Dual Immune Cell Targeting BsAb an Immuno-Oncology, ABL301 an BBB-Penetrating Bispecific Antibody.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 102
- Website
- https://www.ablbio.com
Comparables
Valuation
|
Metric
|
298380
|
235980
|
068270
|
|---|---|---|---|
Price/Earnings (Normalized) | 374.65 | — | 89.53 |
Price/Book Value | 62.35 | 3.41 | 2.39 |
Price/Sales | 47.26 | — | 12.63 |
Price/Cash Flow | — | — | 49.49 |
Price/Earnings
298380
235980
068270
Financial Strength
|
Metric
|
298380
|
235980
|
068270
|
|---|---|---|---|
Quick Ratio | 1.49 | 7.95 | 0.75 |
Current Ratio | 1.55 | 8.14 | 1.82 |
Interest Coverage | −47.33 | −327.64 | 9.77 |
Quick Ratio
298380
235980
068270
Profitability
|
Metric
|
298380
|
235980
|
068270
|
|---|---|---|---|
Return on Assets (Normalized) | −22.14% | −46.94% | 2.21% |
Return on Equity (Normalized) | −78.54% | −56.94% | 2.72% |
Return on Invested Capital (Normalized) | −30.43% | −53.74% | 2.45% |
Return on Assets
298380
235980
068270
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Cyhvbwqcp | Gwvdb | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Vlgbtmf | Pqgndm | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Npmqcywg | Yxbrnnx | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Lljwyssg | Jkvmrg | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Pypjmkq | Pppp | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Dztydhtm | Jbrb | $29.2 Bil | |||
| Moderna Inc
MRNA
| Qfszstkj | Fgx | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Brdwvctb | Ghzc | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Hjypxnzx | Gjgjfq | $13.2 Bil | |||
| Incyte Corp
INCY
| Htlhxys | Mbvchr | $13.0 Bil |
United States